October's top stories: Orexigen files authorisation application for Contrave
Orexigen has submitted a marketing authorisation application to the European Medicines Agency for its Contrave drug, while Xencor has dosed the first patient in the Phase IIa, part of its ongoing Phase Ib/IIa clinical trial of XmAb5871 for rheumatoid arthritis, an autoimmune disease. Drugdevelopment-technology.com wraps up the key headlines from October 2013.
September's top stories: Takeda gets EU approval for type 2 diabetes therapies
Takeda has received marketing authorisation from the European Commission for its three new type 2 diabetes therapies - Vipidia, Vipdomet and Incresync - while Dendreon has received European approval to market its prostate cancer therapy Provenge. Drugdevelopment-technology.com wraps up the key headlines from September 2013.
August's top stories: Bayer, Compugen partner for cancer immunotherapy
Bayer and Compugen have formed a strategic alliance to develop a new cancer treatment, Novartis's Afinitor Phase III trial failed to meet its primary end-point and A*STAR's GIS researchers discovered neurogenesis controlling long non-coding RNA. Drugdevelopment-technology.com wraps up key headlines from August 2013.
July's top stories: Immunocore, Genentech to develop ImmTACs
Immunocore and Genentech have formed a strategic alliance to develop ImmTACs against multiple cancers, while ARTES Biotechnology and Bio Farma have collaborated to develop and manufacture vaccine candidates. Drugdevelopment-technology.com wraps up key headlines from July 2013.
June's top stories: China-Germany quality alliance, AstraZeneca cancer focus
The CCCMHPIE and German Good Manufacturing Practices third party auditor form alliance for drug quality, while Genmab and ADC Therapeutics collaborate to develop new antibody-drug conjugate (ADC) product for multiple cancer indications. Drugdevelopment-technology.com wraps up key headlines from June 2013.